The quality behind Rab Diagnostics pharma services
At Rab Diagnostics, scientific rigor and quality is not just a principle, it’s the foundation of everything we do. Our R&D services are tailored for biopharmaceutical innovators seeking to understand the cellular processing of their antibody-drug conjugates (ADCs) and the impact on efficacy.
Science-Driven, Biomarker-Focused
Our research is anchored in peer-reviewed, published science from world leading cancer research at Oslo University Hospital, including our recent study in Nature Communications , which demonstrates how Rab GTPases regulate the intracellular trafficking and efficacy of HER2-targeted ADCs. This work reflects our unique expertise in cell biology, trafficking pathways, and predictive biomarkers.
Precision Meets Reliability
Whether you wish insights into Rab-GTPase effect on your lead ADC, biomarker discovery and validation, or custom assay development, our in-house team combines deep domain knowledge with robust experimental design and verified setup. We understand the high stakes of translational research and deliver data you can act on with confidence.
Trusted by Biotech Innovators
We operate as an extension of your R&D team, offering transparent collaborations that move your ADC forward faster and smarter. We design the studies and setup in close dialogue with our sponsors and ensure frequent updates and communication during studies. From early discovery, preclinical validation and retrospective expression studies on clinical samples, our services are tailored to meet the specific challenges of developing targeted ADCs for oncology.
Your Partner in Predictive ADC Science
Rab Diagnostics is more than a service provider, we are your strategic partner in precision oncology development. If your team is advancing ADCs, grounded in mechanistic insight, we’re here to help.
Explore our R&D services at www.rabdiagnostics.com or contact us directly to start a conversation.